Brokers Offer Predictions for RenovoRx FY2026 Earnings

Key Points

• HC Wainwright cut its FY2026 EPS forecast to a loss of $0.29 per share from a projected loss of $0.21; the new estimate is also below the consensus loss of $0.24.
• RenovoRx reported a quarterly loss of $0.07 per share, missing analysts’ $0.06 loss estimate, while revenue of $1.07 million slightly exceeded the $1.06 million consensus.
• Analyst views remain mixed: MarketBeat reports a “Moderate Buy” consensus rating and an $8.50 price target, while Wall Street Zen recently downgraded the stock to “Sell.”

RenovoRx, Inc. (NASDAQ:RNXT - Free Report) - Analysts at HC Wainwright lowered their FY2026 EPS estimates for RenovoRx in a note issued to investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.29) per share for the year, down from their prior estimate of ($0.21). The consensus estimate for RenovoRx's current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for RenovoRx's Q4 2026 earnings at ($0.06) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.03) EPS, FY2029 earnings at $0.08 EPS and FY2030 earnings at $0.18 EPS.

RenovoRx (NASDAQ:RNXT - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 135.11% and a negative net margin of 621.71%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.06 million.

RNXT has been the subject of a number of other research reports. Weiss Ratings upgraded shares of RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, September 2nd. Wall Street Zen cut RenovoRx from a "hold" rating to a "sell" rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, RenovoRx currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

RenovoRx Trading Up 4.4%

NASDAQ:RNXT opened at $1.18 on Tuesday. The company's 50-day moving average is $1.53 and its two-hundred day moving average is $1.11. RenovoRx has a 1-year low of $0.70 and a 1-year high of $2.59.

Hedge Funds Weigh In On RenovoRx

An institutional investor recently bought a new stake in RenovoRx stock. T3 Companies LLC bought a new stake in RenovoRx, Inc. (NASDAQ:RNXT - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 96,800 shares of the company's stock, valued at approximately $151,000. T3 Companies LLC owned about 0.21% of RenovoRx as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 3.10% of the company's stock.

Key RenovoRx News

Here are the key news stories impacting RenovoRx this week:

• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.29 from $0.21 and its FY2027 estimate to a loss of $0.19 from $0.04. It also raised projected losses for Q4 2026 and each of the first three quarters of 2027. HC Wainwright Estimates RenovoRx's Q4 Earnings
• Negative Sentiment: The analyst also reduced longer-term forecasts: FY2028 moved from expected EPS of $0.08 to a loss of $0.03; FY2029 fell from $0.18 to $0.08, and FY2030 from $0.26 to $0.18. Though profitability is still projected in 2029 and 2030, the cuts point to a slower earnings outlook.
• Negative Sentiment: Wall Street Zen lowered its rating on RNXT to “Sell,” adding another bearish signal. RenovoRx Rating Lowered to Sell at Wall Street Zen

About RenovoRx

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company's approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx's lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.